Neuraxis highlights two independent studies showing benefits of ib-stim in adolescents involving the gut microbiome

Carmel, ind., aug. 22, 2023 (globe newswire) -- neuraxis, inc. (nyse american: nrxs), (“neuraxis,” or the “company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today highlights two recently published independent studies showing that ib-stim therapy leads to improvements in abdominal pain and disability in adolescents with ibs and that the gut microbiome may play an important role.
NRXS Ratings Summary
NRXS Quant Ranking